Prevención de la neumonía del adulto adquirida en la comunidad

Polysaccharide 23 valent pneumococcal vaccine commercially available from 1983 includes 23 serotypes of Streptococcus pneumoniae, representing near 90% of strains involved in invasive pneumococcal disease in immune competent adults. Vaccine confers protection against invasive pneumococcal disease. I...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Barros M,Manuel, Cartagena S,Claudia, Bavestrello F,Luis
Lenguaje:	Spanish / Castilian
Publicado:	Sociedad Chilena de Infectología 2005
Materias:	neumonía medidas preventivas profilaxis prevención y control
Acceso en línea:	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0716-10182005000400009
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:scielo:S0716-10182005000400009
record_format	dspace
spelling	oai:scielo:S0716-101820050004000092005-12-06Prevención de la neumonía del adulto adquirida en la comunidadBarros M,ManuelCartagena S,ClaudiaBavestrello F,Luis neumonía medidas preventivas profilaxis prevención y control Polysaccharide 23 valent pneumococcal vaccine commercially available from 1983 includes 23 serotypes of Streptococcus pneumoniae, representing near 90% of strains involved in invasive pneumococcal disease in immune competent adults. Vaccine confers protection against invasive pneumococcal disease. Immunization is recommended in adults over 65 years old, in patients affected by chronic diseases (cardiopathies, COPD, nephropathies, diabetes mellitus, hepatic cirrhosis, chronic breakage in brain-blood barrier, functional or anatomical asplenia, alcoholism), in immunocompromised hosts, including HIV infection, chemotherapy treatment and hematological malignancies. Influenza vaccine is prepared with particulated antigens, including two influenza A strains and one influenza B strain, selected according to influenza epidemiological worldwide surveillance the year before. On account of continuous antigenic changes (drifts), it is necessary to modify the vaccine antigen's composition yearly. Cost/effectiveness evaluation has confirmed the efficacy of influenza vaccine in reducing morbidity and mortality associated to influenza epidemic and health economical resources involved in patient care. Besides, clinical trials have confirmed that immunization reduces the risk of acquiring pneumonia, of hospitalization and death in elderly people during the influenza epidemic, when vaccine antigenic composition is similar to the circulating strains. Vaccination is recommended annually in healthy adults over 65 years old, in patients with chronic diseases (cardiopathies, COPD, nephropathies, diabetes mellitus, hepatic cirrhosis, chronic breakage of blood-brain barrier, functional or anatomical asplenia, alcoholism). It is also recommended in women who will be in the second or third trimester of pregnancy during the influenza season, in immunocompromised hosts, in institutionalized patients (geriatrics), health care workers, and travelers to geographical areas that are affected by the influenza epidemicinfo:eu-repo/semantics/openAccessSociedad Chilena de InfectologíaRevista chilena de infectología v.22 suppl.1 20052005-01-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0716-10182005000400009es10.4067/S0716-10182005000400009
institution	Scielo Chile
collection	Scielo Chile
language	Spanish / Castilian
topic	neumonía medidas preventivas profilaxis prevención y control
spellingShingle	neumonía medidas preventivas profilaxis prevención y control Barros M,Manuel Cartagena S,Claudia Bavestrello F,Luis Prevención de la neumonía del adulto adquirida en la comunidad
description	Polysaccharide 23 valent pneumococcal vaccine commercially available from 1983 includes 23 serotypes of Streptococcus pneumoniae, representing near 90% of strains involved in invasive pneumococcal disease in immune competent adults. Vaccine confers protection against invasive pneumococcal disease. Immunization is recommended in adults over 65 years old, in patients affected by chronic diseases (cardiopathies, COPD, nephropathies, diabetes mellitus, hepatic cirrhosis, chronic breakage in brain-blood barrier, functional or anatomical asplenia, alcoholism), in immunocompromised hosts, including HIV infection, chemotherapy treatment and hematological malignancies. Influenza vaccine is prepared with particulated antigens, including two influenza A strains and one influenza B strain, selected according to influenza epidemiological worldwide surveillance the year before. On account of continuous antigenic changes (drifts), it is necessary to modify the vaccine antigen's composition yearly. Cost/effectiveness evaluation has confirmed the efficacy of influenza vaccine in reducing morbidity and mortality associated to influenza epidemic and health economical resources involved in patient care. Besides, clinical trials have confirmed that immunization reduces the risk of acquiring pneumonia, of hospitalization and death in elderly people during the influenza epidemic, when vaccine antigenic composition is similar to the circulating strains. Vaccination is recommended annually in healthy adults over 65 years old, in patients with chronic diseases (cardiopathies, COPD, nephropathies, diabetes mellitus, hepatic cirrhosis, chronic breakage of blood-brain barrier, functional or anatomical asplenia, alcoholism). It is also recommended in women who will be in the second or third trimester of pregnancy during the influenza season, in immunocompromised hosts, in institutionalized patients (geriatrics), health care workers, and travelers to geographical areas that are affected by the influenza epidemic
author	Barros M,Manuel Cartagena S,Claudia Bavestrello F,Luis
author_facet	Barros M,Manuel Cartagena S,Claudia Bavestrello F,Luis
author_sort	Barros M,Manuel
title	Prevención de la neumonía del adulto adquirida en la comunidad
title_short	Prevención de la neumonía del adulto adquirida en la comunidad
title_full	Prevención de la neumonía del adulto adquirida en la comunidad
title_fullStr	Prevención de la neumonía del adulto adquirida en la comunidad
title_full_unstemmed	Prevención de la neumonía del adulto adquirida en la comunidad
title_sort	prevención de la neumonía del adulto adquirida en la comunidad
publisher	Sociedad Chilena de Infectología
publishDate	2005
url	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0716-10182005000400009
work_keys_str_mv	AT barrosmmanuel prevenciondelaneumoniadeladultoadquiridaenlacomunidad AT cartagenasclaudia prevenciondelaneumoniadeladultoadquiridaenlacomunidad AT bavestrellofluis prevenciondelaneumoniadeladultoadquiridaenlacomunidad
_version_	1718440088112726016

Prevención de la neumonía del adulto adquirida en la comunidad

Ejemplares similares